CAPLYTA

all catalysts(0)

nothing on the calendar yet

News(3)

• An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
  Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
  biopharma_dive · 11d ago
• As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
  Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…
  biospace · 1mo ago
• J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
  J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
  biopharma_dive · 2mo ago